Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | LIG1 | P18858 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047876 | 0.90 | BRD4 (0.42) | BRD4BACE1LIG1CNR1HSD17B10 | |
| SCHEMBL2052237 | 0.90 | BRD4 (0.42) | BRD4BACE1LIG1CNR1HSD17B10 | |
| SCHEMBL2047677 | 0.90 | BRD4 (0.42) | BRD4BACE1LIG1CNR1HSD17B10 | |
| SCHEMBL2052239 | 0.90 | BRD4 (0.42) | BRD4BACE1LIG1CNR1HSD17B10 | |
| SCHEMBL4167991 | 0.90 | BRD4 (0.42) | BRD4BACE1LIG1CNR1HSD17B10 | |
| SCHEMBL12588137 | 0.76 | LIG1 (0.36) | BRD4LIG1HSD17B10CYP3A4CYP2C9 | |
| SCHEMBL14140427 | 0.76 | CYP19A1 (0.40) | — | |
| SCHEMBL14144956 | 0.76 | SIGMAR1 (0.31) | BACE1FPR2TSHRLMNA | |
| SCHEMBL14140687 | 0.76 | SIGMAR1 (0.31) | BACE1FPR2TSHRLMNA | |
| SCHEMBL2314759 | 0.76 | POLB (0.51) | CNR1FPR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956195-B2 | reacting arylboronic acids with a cycloalkanone, in the presence of a rhodium catalyst or BINAP, to form a substituted arylcycloalkanone, then formin of a hydantoin, alkylation of the hydantoin, resolution, hydrolysis of the hydantoin to the amino acids and esterification of acids; chemical intermediates | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | ABBVIE INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255367-A1 | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates | DDC, DNPEP, AAAS | BRD4 2791/4885BACE1 1459/4885LIG1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.